ARCHIVES

Two Phase II Studies of Ibrutinib Deliver High Response Rates

This article is from The Cancer Letter archive.

Vol. 36 No. 12 | December 27, 2013

Download PDF Visit The Full Archive

Related Articles

Program Announcements n Animal Retroviruses, Other Topics, Approved

March 30, 1990

New Phase III Trial Reviews Approve 25%; Should Trialists Worry? Not Yet,

January 19, 2007

Slow Accruing Trials Should Be Removed From High Priority Program, Broder Says

October 2, 1992

ODAC Recommends Femara Campath For FDA Approval.

January 5, 2001

NCI selects nanotech centers for funding.

October 14, 2005

Patients Report Clinical Trials Not Offered By Physician

June 27, 2008